Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $2.05, $0.03 worse than the analyst estimate of $2.08. Revenue for the quarter came in at $288.2 million versus the consensus estimate of $287.12 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.